General counsel Mark Nance joined Insys Therapeutics Inc. in October as the company was working toward settling civil and criminal allegations that it bribed doctors to prescribe one of its popular opioid drugs. But if Nance was part of the $225 million global settlement announced Wednesday, there was no outward sign of it.

Nance’s name was not on the five-year deferred prosecution agreement that Insys accepted, nor on the five-year corporate integrity agreement—which the government called an “unprecedented” deal. It includes a “conditional exclusion release” that allows the government to exclude the company from federal contracts, such as Medicare, if it materially breaches the terms.